Clinical Trial Update: Open Label Study to Evaluate Safety and Efficacy of 2 Doses of Quizartinib in Patients With Relapsed or Refractory Acute Myeloid Leukemia [Phase 2]

View source ↗

Summary

Phase 2 open-label study evaluating safety and efficacy of two doses of quizartinib in relapsed or refractory acute myeloid leukemia has completed with results …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• Quizartinib (Quizartinib)

Snippet

Sponsor: Daiichi Sankyo | Conditions: Leukemia, Myeloid, Acute | Phase 2 | Status: COMPLETED | Results posted: 2019-12-27